WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site

In a move that revolutionizes high potency pharmaceuticals manufacturing, WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a high potency, fully automated sterile injectable manufacturing line at its Wuxi City site. This step significantly boosts the company’s ability to cater to the soaring demands in the pharmaceutical sector.

One of the hallmarks of this manufacturing line is its stringent compliance with Occupational Exposure Limits (OEL), as low as 10 ng/m3, and its use of fully enclosed isolation systems. Additionally, the incorporation of an independent air conditioning system and a bag-in bag-out (BIBO) exhaust air purification system ensures a secure operational environment and quality control.

This landmark development is just one phase of WuXi STA’s grand vision. By 2024, the company is set to introduce two more injectable manufacturing lines at the same site, underlining its commitment to technological innovation and patient care. As Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, states, WuXi STA is steadfast in its mission to “accelerate pharmaceutical development and bring new therapeutics for patients worldwide.”